Top Analyst Stands Firm for Acadia Pharmaceutical (ACAD) Stock While its Anti-Depression Medication Goes Through Trial

After a series of talks with depression key opinion leaders (KOL) about Acadia Pharmaceutical’s (ACAD) Ph2 CLARITY trial, all four experts believe the …

Acadia Pharmaceuticals (ACAD): Another Glimpse Into Nuplazid Safety Profile

Acadia Pharmaceuticals (NASDAQ:ACAD) is a biopharmaceutical company based in San Diego and focused on the development of therapeutics to treat central nervous system …

ACADIA Pharmaceuticals (ACAD): Top Analyst Does Not See ‘Real Safety Signal’ for Nuplazid

Cowen’s Ritu Baral’s conversations with key experts in the field with Nuplazid experience leave her positive; albeit somewhat ‘cautious’ on the impact of ACAD’s controversy.

Here’s Why ACADIA Pharmaceuticals Stock Is Plummeting 25% Today

ACADIA Pharmaceuticals (NASDAQ:ACAD) just got hit with a bad bullet: a CNN research report questioning lead asset Nuplazid’s risk/reward as a treatment of …

Here’s Why ACADIA Pharmaceuticals Inc. (ACAD) Shares Are Diving Today

Has Wall Street gone a bit overboard punishing ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD)?

ACADIA Pharmaceuticals Inc. (ACAD) Gets a Price Target Jump; Here’s Why

One of Wall Street’s best performing analysts sees strong long-term care growth for ACAD’s Nuplazid.

ACADIA Pharmaceuticals Inc. (ACAD) 3Q:17 Net Sales Grew to $35.6 Million

ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) announced its unaudited financial results for the third quarter ended September 30, 2017.

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts